INDP Indaptus Therapeutics Inc

$INDP — INDP continues to be one of the wildest smaller healthcare names after gaining roughly 249% during September. The company raised around $24M and is exploring early research around a sleep-related device following the Decoy20 reset. That makes this less about the old pipeline and more about what management decides to do with its newly raised capital. Definitely a speculative one, but the strategic pivot has kept retail attention elevated

$INDP — INDP has basically become a corporate-reset story. After discontinuing Decoy20 enrollment, the company raised roughly $24M and began exploring a new sleep/neurotechnology direction. With fresh capital and a completely different potential strategy, the important question now is what management actually decides to build or acquire. 👀